Synergistic Effect between Cisplatin and Sunitinib Malate on Human Urinary Bladder-Cancer Cell Lines

Table 2

Cell-cycle distribution of HT1376, T24, and 5637 urinary bladder-cancer cell lines, after treatment with cisplatin and sunitinib malate, in isolation or combined. G₀/G₁, S, and G₂/M values are mean ± SD of the three independent experiments.

	HT1376			T24			5637
	G0/G1	S	G2/M	G0/G1	S	G2/M	G0/G1	S	G2/M
Control	75.9±5.8	10.4±0.5	13.6±1.2	91.6±2.3	2.7±0.2	5.8±1.8	81.1±3.9	7.4±0.7	11.6±1.1
Cisplatin (3 𝜇M)	45.9±5.7	39.2±1.6	14.8±4	71.5±2	18.2±1.5	10.2±1	24.1±1.2	63.9±2.4	11.9±0.9
Sunitinib malate (1 μM)	77±4.5	11.7±0.8	11.2±1.7	93.7±1.1	2.2±0.1	4±0.1	72.1±2.4	11.6±0.6	16.3±1.6
Sunitinib malate (2 μM)	78.7±3.8	10.9±1.4	10.1±1.3	93.7±2.2	2.4±0.2	4.2±0.5	71.6±0.8	13.2±0.2	15.1±0.5
Sunitinib malate (4 𝜇M)	78.2±3.3	12.5±0.9	9.2±1.2	93.9±3.5	2.5±0.2	3.5±0.1	69.7±2.7	14.5±0.1	15.8±1.1
Cisplatin (3 𝜇M) +; Sunitinib malate (1 𝜇M)	52.4±0.4	35.6±0.7	11.9±0.4	72±3.2	18.6±1.4	9.4±1.5	32.1±0.3	61.5±3.4	6.4±0.7
Cisplatin (3 μM) +; Sunitinib malate (2 𝜇M)	56.4±2.9	34.4±3.2	9.1±0.5	74.6±3.6	17.1±1.3	8.3±0.8	39.7±3.2	54.2±6.1	6.1±0.4
Cisplatin (3 μM) +; Sunitinib malate (4 𝜇M)	56.8±1.8	34.3±1.2	8.8±0.3	74.9±2.7	12.2±1	7.8±2	38.8±5.1	54.9±2.9	6.2±0.7

SD: standard deviation.